Weidong Gan
Overview
Explore the profile of Weidong Gan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lu Q, Zhao X, Zhang S, Wang G, Ji C, Liu G, et al.
Eur Urol Oncol
. 2023 Aug;
7(2):275-281.
PMID: 37598032
Background: Although partial nephrectomy has become the gold standard for T1 renal tumors whenever technically feasible, simple enucleation has shown superior results. To the best of our knowledge, no randomized...
12.
Lu Y, Zhu Y, Ma W, Liu N, Dong X, Shi Q, et al.
Sci Rep
. 2023 Apr;
13(1):6141.
PMID: 37061606
Based on the epidemiological characteristics of susceptibility and age selectivity for women in Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC), we inferred that estrogen was to be blamed. Rad54 like...
13.
Zhou S, Lu Y, Chen Y, Gan W
Sci Rep
. 2023 Mar;
13(1):4449.
PMID: 36932108
Immunogenic cell death (ICD) is the trigger of adaptive immune responses. However, the role of ICD-related genes in clear cell renal carcinoma (ccRCC) remains unclear. We aimed to identify biomarkers...
14.
Guo W, Zhu Y, Pu X, Guo H, Gan W
Front Oncol
. 2023 Feb;
13:1116648.
PMID: 36816933
Background: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a group of rare and highly heterogeneous renal cell carcinoma (RCC). The translocation involving TFE3 and different fusion partners lead to...
15.
Yang Y, Qin H, Ding M, Ji C, Chen W, Diao W, et al.
FEBS Open Bio
. 2022 Dec;
13(2):257-269.
PMID: 36508323
Docetaxel (DTX) plays an important role in treating advanced prostate cancer (PCa). However, nearly all patients receiving DTX therapy ultimately progress to DTX resistance. How to address DTX resistance in...
16.
Ma W, Li X, Yang L, Pan J, Chen Y, Lu Y, et al.
J Transl Med
. 2022 Dec;
20(1):554.
PMID: 36463181
Background: Clear cell renal cell carcinoma (ccRCC), the most common urological malignancy, has an unfavorable prognosis and an unknown mechanism of progression. Through survival analyses screening of The Cancer Genome...
17.
Yang L, Yin H, Chen Y, Pan C, Hang H, Lu Y, et al.
Exp Hematol Oncol
. 2022 Nov;
11(1):87.
PMID: 36348434
Background: Pseudogenes play an essential role in tumor occurrence and progression. However, the functions and mechanisms of pseudogenes in clear cell renal cell carcinoma (ccRCC) remain largely elusive. Methods: We...
18.
Dong X, Chen Y, Pan J, Ma W, Zhou P, Chen M, et al.
Front Oncol
. 2022 Oct;
12:1017425.
PMID: 36276115
Background: This study aimed to investigate the expression profile of TFE3 in renal cell carcinoma (RCC) and the clinicopathological features as well as prognosis of TFE3-positive RCC. Methods: Tissue sections...
19.
Yang L, Chen Y, Liu N, Lu Y, Li X, Ma W, et al.
Biomark Res
. 2022 Jul;
10(1):54.
PMID: 35897085
Background: In our previous study, we found that lncRNA TRAF3IP2 antisense RNA 1 (TRAF3IP2-AS1) could play a critical role in the progression of NONO-TFE3 translocation renal cell carcinoma (NONO-TFE3 tRCC)....
20.
Dong X, Pan S, Zhou X, Ma W, Guo H, Gan W
Cancer Med
. 2022 Jun;
12(2):1260-1268.
PMID: 35766142
Background: The aim of this study was to investigate the peritumoral pseudocapsule (PC) status and identify the factors influencing PC status in small renal cell carcinoma (RCCs). Methods: A total...